25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

ALPMY (Astellas) Stock Analysis
Buy, Hold or Sell?

Let's analyze Astellas together

I guess you are interested in Astellas Pharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

  • πŸ“Š Fundamental Analysis (FA) – Astellas’s Financial Insights
  • πŸ“ˆ Technical Analysis (TA) – Astellas’s Price Targets

I'm going to help you getting a better view of Astellas Pharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Astellas Pharma Inc

I send you an email if I find something interesting about Astellas Pharma Inc.

1. Quick Overview

1.1. Quick analysis of Astellas (30 sec.)










1.2. What can you expect buying and holding a share of Astellas? (30 sec.)

How much money do you get?

How much money do you get?
$1.71
When do you have the money?
1 year
How often do you get paid?
100.0%

What is your share worth?

Current worth
$5.85
Expected worth in 1 year
$7.45
How sure are you?
100.0%

+ What do you gain per year?

Total Gains per Share
$3.31
Return On Investment
33.5%

For what price can you sell your share?

Current Price per Share
$9.87
Expected price per share
$9.12 - $11.03
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Astellas (5 min.)




Live pricePrice per Share (EOD)
$9.87
Intrinsic Value Per Share
$-1.46 - $4.55
Total Value Per Share
$4.40 - $10.40

2.2. Growth of Astellas (5 min.)




Is Astellas growing?

Current yearPrevious yearGrowGrow %
How rich?$10.5b$9.9b$581m5.5%

How much money is Astellas making?

Current yearPrevious yearGrowGrow %
Making money$112.4m$651.5m-$539m-479.1%
Net Profit Margin1.1%6.5%--

How much money comes from the company's main activities?

2.3. Financial Health of Astellas (5 min.)




3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Astellas?

Welcome investor! Astellas's management wants to use your money to grow the business. In return you get a share of Astellas.

First you should know what it really means to hold a share of Astellas. And how you can make/lose money.

Speculation

The Price per Share of Astellas is $9.87. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Astellas.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Astellas, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.85. Based on the TTM, the Book Value Change Per Share is $0.40 per quarter. Based on the YOY, the Book Value Change Per Share is $0.25 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.43 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Astellas.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.060.6%0.060.6%0.363.6%0.404.0%0.464.6%
Usd Book Value Change Per Share0.404.1%0.404.1%0.252.5%0.313.2%0.212.2%
Usd Dividend Per Share0.434.3%0.434.3%0.363.7%0.323.3%0.272.8%
Usd Total Gains Per Share0.838.4%0.838.4%0.616.2%0.646.4%0.494.9%
Usd Price Per Share10.74-10.74-14.15-14.30-14.46-
Price to Earnings Ratio171.76-171.76-39.63-61.09-275.18-
Price-to-Total Gains Ratio12.97-12.97-23.27-23.50-37.79-
Price to Book Ratio1.83-1.83-2.59-2.80-3.21-
Price-to-Total Gains Ratio12.97-12.97-23.27-23.50-37.79-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share9.87
Number of shares101
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.430.32
Usd Book Value Change Per Share0.400.31
Usd Total Gains Per Share0.830.64
Gains per Quarter (101 shares)83.5964.27
Gains per Year (101 shares)334.36257.09
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1173162324131126247
2346323658262252504
3519485992394378761
469164613265255041018
586480816606566291275
6103796919947877551532
71210113123289188811789
8138312922662105010072046
9155614542996118111332303
10172816153330131212592560

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%21.00.00.0100.0%
Book Value Change Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.01.00.090.0%16.05.00.076.2%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%21.00.00.0100.0%
Total Gains per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%10.00.00.0100.0%19.02.00.090.5%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Astellas Pharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.4000.4000%0.245+63%0.312+28%0.213+88%
Book Value Per Share--5.8535.8530%5.453+7%5.194+13%4.613+27%
Current Ratio--0.9290.9290%1.446-36%1.256-26%1.666-44%
Debt To Asset Ratio--0.5530.5530%0.386+43%0.429+29%0.367+51%
Debt To Equity Ratio--1.2371.2370%0.629+97%0.780+59%0.609+103%
Dividend Per Share--0.4280.4280%0.363+18%0.325+32%0.272+57%
Enterprise Value--8702599020.0008702599020.0000%22047584628.000-61%21105319481.800-59%25173313397.784-65%
Eps--0.0630.0630%0.357-82%0.395-84%0.455-86%
Ev To Ebitda Ratio--6.7686.7680%13.531-50%12.820-47%13.191-49%
Ev To Sales Ratio--0.8220.8220%2.200-63%2.372-65%2.887-72%
Free Cash Flow Per Share--0.3300.3300%0.865-62%0.632-48%0.645-49%
Free Cash Flow To Equity Per Share--2.5822.5820%0.158+1537%0.751+244%0.411+527%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--4.548--------
Intrinsic Value_10Y_min---1.458--------
Intrinsic Value_1Y_max--0.606--------
Intrinsic Value_1Y_min--0.426--------
Intrinsic Value_3Y_max--1.705--------
Intrinsic Value_3Y_min--0.793--------
Intrinsic Value_5Y_max--2.667--------
Intrinsic Value_5Y_min--0.621--------
Market Cap17668483768.320-9%19322949420.00019322949420.0000%25820963028.000-25%26393190641.800-27%28468560077.784-32%
Net Profit Margin--0.0110.0110%0.065-84%0.084-87%0.113-91%
Operating Margin--0.0230.0230%0.093-75%0.125-82%0.184-87%
Operating Ratio--0.9840.9840%0.812+21%0.842+17%0.823+20%
Pb Ratio1.686-9%1.8341.8340%2.594-29%2.799-34%3.212-43%
Pe Ratio157.894-9%171.764171.7640%39.632+333%61.094+181%275.185-38%
Price Per Share9.870-9%10.73710.7370%14.148-24%14.302-25%14.457-26%
Price To Free Cash Flow Ratio29.911-9%32.53832.5380%16.354+99%24.549+33%23.872+36%
Price To Total Gains Ratio11.926-9%12.97312.9730%23.266-44%23.501-45%37.786-66%
Quick Ratio--0.7220.7220%1.136-36%0.984-27%1.332-46%
Return On Assets--0.0050.0050%0.040-88%0.047-90%0.075-94%
Return On Equity--0.0110.0110%0.065-84%0.080-87%0.114-91%
Total Gains Per Share--0.8280.8280%0.608+36%0.636+30%0.485+71%
Usd Book Value--10533520800.00010533520800.0000%9952496400.000+6%9556184880.000+10%8986001640.000+17%
Usd Book Value Change Per Share--0.4000.4000%0.245+63%0.312+28%0.213+88%
Usd Book Value Per Share--5.8535.8530%5.453+7%5.194+13%4.613+27%
Usd Dividend Per Share--0.4280.4280%0.363+18%0.325+32%0.272+57%
Usd Enterprise Value--8702599020.0008702599020.0000%22047584628.000-61%21105319481.800-59%25173313397.784-65%
Usd Eps--0.0630.0630%0.357-82%0.395-84%0.455-86%
Usd Free Cash Flow--593854800.000593854800.0000%1578891600.000-62%1166499840.000-49%1265692560.000-53%
Usd Free Cash Flow Per Share--0.3300.3300%0.865-62%0.632-48%0.645-49%
Usd Free Cash Flow To Equity Per Share--2.5822.5820%0.158+1537%0.751+244%0.411+527%
Usd Market Cap17668483768.320-9%19322949420.00019322949420.0000%25820963028.000-25%26393190641.800-27%28468560077.784-32%
Usd Price Per Share9.870-9%10.73710.7370%14.148-24%14.302-25%14.457-26%
Usd Profit--112497000.000112497000.0000%651512400.000-83%733715400.000-85%984081780.000-89%
Usd Revenue--10584235200.00010584235200.0000%10022885400.000+6%9198849000.000+15%8914698540.000+19%
Usd Total Gains Per Share--0.8280.8280%0.608+36%0.636+30%0.485+71%
 EOD+4 -4MRQTTM+0 -0YOY+14 -255Y+14 -2510Y+15 -24

3.3 Fundamental Score

Let's check the fundamental score of Astellas Pharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15157.894
Price to Book Ratio (EOD)Between0-11.686
Net Profit Margin (MRQ)Greater than00.011
Operating Margin (MRQ)Greater than00.023
Quick Ratio (MRQ)Greater than10.722
Current Ratio (MRQ)Greater than10.929
Debt to Asset Ratio (MRQ)Less than10.553
Debt to Equity Ratio (MRQ)Less than11.237
Return on Equity (MRQ)Greater than0.150.011
Return on Assets (MRQ)Greater than0.050.005
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Astellas Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.126
Ma 20Greater thanMa 509.873
Ma 50Greater thanMa 1009.720
Ma 100Greater thanMa 20010.001
OpenGreater thanClose9.870
Total2/5 (40.0%)

4. In-depth Analysis

4.1 About Astellas Pharma Inc

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Fundamental data was last updated by Penke on 2025-03-07 10:12:03.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is less efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just not able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is fair priced.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profitΒ Astellas earns for each $1 of revenue.

  • Above 10% is considered healthy but always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • A Net Profit Margin of 1.1%Β means thatΒ $0.01 for each $1Β in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Astellas Pharma Inc:

  • The MRQ is 1.1%. The company is making a profit. +1
  • The TTM is 1.1%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ1.1%TTM1.1%0.0%
TTM1.1%YOY6.5%-5.4%
TTM1.1%5Y8.4%-7.3%
5Y8.4%10Y11.3%-3.0%
4.3.1.2. Return on Assets

Shows howΒ efficientΒ Astellas is using its assets to generate profit.

  • Above 5% is considered healthyΒ but always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • 0.5% Return on Assets means thatΒ Astellas generatedΒ $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Astellas Pharma Inc:

  • The MRQ is 0.5%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.5%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.5%TTM0.5%0.0%
TTM0.5%YOY4.0%-3.5%
TTM0.5%5Y4.7%-4.2%
5Y4.7%10Y7.5%-2.7%
4.3.1.3. Return on Equity

Shows how efficient Astellas is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • 1.1% Return on Equity means Astellas generated $0.01Β for eachΒ $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Astellas Pharma Inc:

  • The MRQ is 1.1%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.1%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.1%TTM1.1%0.0%
TTM1.1%YOY6.5%-5.5%
TTM1.1%5Y8.0%-6.9%
5Y8.0%10Y11.4%-3.4%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Astellas Pharma Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

MeasuresΒ how efficient Astellas is operatingΒ .

  • Measures how much profit Astellas makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • An Operating Margin of 2.3%Β means the company generated $0.02 Β for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Astellas Pharma Inc:

  • The MRQ is 2.3%. The company is operating less efficient.
  • The TTM is 2.3%. The company is operating less efficient.
Trends
Current periodCompared to+/- 
MRQ2.3%TTM2.3%0.0%
TTM2.3%YOY9.3%-7.0%
TTM2.3%5Y12.5%-10.2%
5Y12.5%10Y18.4%-5.9%
4.3.2.2. Operating Ratio

Measures how efficient Astellas is keepingΒ operating costsΒ low.

  • Below 1 is considered healthy (always compare toΒ Drug Manufacturers - General industry mean).
  • An Operation Ratio of 0.98 means that the operating costs are $0.98 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.984. The company is less efficient in keeping operating costs low.
  • The TTM is 0.984. The company is less efficient in keeping operating costs low.
Trends
Current periodCompared to+/- 
MRQ0.984TTM0.9840.000
TTM0.984YOY0.812+0.172
TTM0.9845Y0.842+0.142
5Y0.84210Y0.823+0.019
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Astellas Pharma Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Astellas is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare toΒ Drug Manufacturers - General industry mean).
  • A Current Ratio of 0.93Β means the company has $0.93 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.929. The company is just not able to pay all its short-term debts. -1
  • The TTM is 0.929. The company is just not able to pay all its short-term debts. -1
Trends
Current periodCompared to+/- 
MRQ0.929TTM0.9290.000
TTM0.929YOY1.446-0.517
TTM0.9295Y1.256-0.326
5Y1.25610Y1.666-0.411
4.4.3.2. Quick Ratio

Measures if Astellas is able to pay off Short-term Debt but only usingΒ theΒ most liquid assets.

  • Above 1 is considered healthy butΒ always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • A Quick Ratio of 0.72Β means the company can pay off $0.72 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.722. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.722. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.722TTM0.7220.000
TTM0.722YOY1.136-0.414
TTM0.7225Y0.984-0.262
5Y0.98410Y1.332-0.348
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Astellas Pharma Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much %Β of AstellasΒ assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compareΒ Astellas to Drug Manufacturers - General industry mean.
  • A Debt to Asset Ratio of 0.55Β means that Astellas assets areΒ financed with 55.3% credit (debt) and the remaining percentage (100% - 55.3%)Β is financed by its owners/shareholders.Β 

Let's take a look of the Debt to Asset Ratio trends of Astellas Pharma Inc:

  • The MRQ is 0.553. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.553. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.553TTM0.5530.000
TTM0.553YOY0.386+0.167
TTM0.5535Y0.429+0.124
5Y0.42910Y0.367+0.063
4.5.4.2. Debt to Equity Ratio

Measures ifΒ Astellas is able toΒ pay off its debts by usingΒ shareholders equity.

  • Below 2 is considered healthy butΒ always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • A Debt to Equity ratio of 123.7% means that company has $1.24 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Astellas Pharma Inc:

  • The MRQ is 1.237. The company is able to pay all its debts with equity. +1
  • The TTM is 1.237. The company is able to pay all its debts with equity. +1
Trends
Current periodCompared to+/- 
MRQ1.237TTM1.2370.000
TTM1.237YOY0.629+0.608
TTM1.2375Y0.780+0.457
5Y0.78010Y0.609+0.171
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

MeasuresΒ how much money you payΒ for each share forΒ every $1 in earnings Astellas generates.

  • Above 15 is considered overpriced butΒ always compareΒ Astellas to theΒ Drug Manufacturers - General industry mean.
  • A PE ratio of 171.76 means the investor is paying $171.76Β for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Astellas Pharma Inc:

  • The EOD is 157.894. Based on the earnings, the company is expensive. -2
  • The MRQ is 171.764. Based on the earnings, the company is expensive. -2
  • The TTM is 171.764. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD157.894MRQ171.764-13.870
MRQ171.764TTM171.7640.000
TTM171.764YOY39.632+132.132
TTM171.7645Y61.094+110.670
5Y61.09410Y275.185-214.091
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Astellas Pharma Inc:

  • The EOD is 29.911. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The MRQ is 32.538. Based on how much money comes from the company's main activities, the company is fair priced.
  • The TTM is 32.538. Based on how much money comes from the company's main activities, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD29.911MRQ32.538-2.627
MRQ32.538TTM32.5380.000
TTM32.538YOY16.354+16.184
TTM32.5385Y24.549+7.989
5Y24.54910Y23.872+0.677
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price ofΒ Astellas is to cheap or to expensiveΒ compared to its book value.

  • At or below 1 is considered healthyΒ (always compare to Drug Manufacturers - General industry mean).
  • A PB ratio of 1.83 means the investor is paying $1.83Β for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Astellas Pharma Inc:

  • The EOD is 1.686. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.834. Based on the equity, the company is underpriced. +1
  • The TTM is 1.834. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.686MRQ1.834-0.148
MRQ1.834TTM1.8340.000
TTM1.834YOY2.594-0.760
TTM1.8345Y2.799-0.965
5Y2.79910Y3.212-0.413
4.6.2. Total Gains per Share
3rd party ad coffee SUPPORTERis ad-free.

6. Financial Statements




6.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2020-03-312021-03-312022-03-312023-03-312024-03-31
Net Working Capital  454,1201,395,3061,849,426-292,2021,557,224580,6482,137,872-2,738,439-600,567



6.2. Latest Balance Sheet

Balance Sheet of 2024-03-31. Currency in JPY. All numbers in thousands.

Summary
Total Assets3,569,603,000
Total Liabilities1,973,615,000
Total Stockholder Equity1,595,988,000
 As reported
Total Liabilities 1,973,615,000
Total Stockholder Equity+ 1,595,988,000
Total Assets = 3,569,603,000

Assets

Total Assets3,569,603,000
Total Current Assets1,194,730,000
Long-term Assets2,374,873,000
Total Current Assets
Cash And Cash Equivalents 335,687,000
Short-term Investments 28,784,000
Net Receivables 534,985,000
Inventory 248,738,000
Other Current Assets 46,536,000
Total Current Assets  (as reported)1,194,730,000
Total Current Assets  (calculated)1,194,730,000
+/-0
Long-term Assets
Property Plant Equipment 293,742,000
Goodwill 418,694,000
Intangible Assets 1,453,824,000
Long-term Assets Other 45,595,000
Long-term Assets  (as reported)2,374,873,000
Long-term Assets  (calculated)2,211,855,000
+/- 163,018,000

Liabilities & Shareholders' Equity

Total Current Liabilities1,285,725,000
Long-term Liabilities687,890,000
Total Stockholder Equity1,595,988,000
Total Current Liabilities
Short-term Debt 472,278,000
Short Long Term Debt 472,278,000
Accounts payable 185,193,000
Other Current Liabilities 589,739,000
Total Current Liabilities  (as reported)1,285,725,000
Total Current Liabilities  (calculated)1,719,488,000
+/- 433,763,000
Long-term Liabilities
Long term Debt 447,738,000
Long-term Liabilities Other 48,962,000
Long-term Liabilities  (as reported)687,890,000
Long-term Liabilities  (calculated)496,700,000
+/- 191,190,000
Total Stockholder Equity
Common Stock103,001,000
Retained Earnings 809,400,000
Other Stockholders Equity 683,587,000
Total Stockholder Equity (as reported)1,595,988,000
Total Stockholder Equity (calculated)1,595,988,000
+/-0
Other
Capital Stock103,001,000
Cash and Short Term Investments 364,471,000
Common Stock Shares Outstanding 1,799,660
Current Deferred Revenue38,515,000
Liabilities and Stockholders Equity 3,569,603,000
Net Debt 584,329,000
Net Invested Capital 2,516,004,000
Net Working Capital -90,995,000
Short Long Term Debt Total 920,016,000



6.3. Balance Sheets Structured

Currency in JPY. All numbers in thousands.

 Trend2024-03-312023-03-312022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-312013-03-312012-03-312011-03-312010-03-312009-03-312008-03-312007-03-312006-03-312005-03-312004-03-31
> Total Assets 
902,698,000
913,563,000
1,584,523,000
1,470,701,000
1,439,152,000
1,348,446,000
1,364,176,000
1,335,091,000
1,400,629,000
1,445,561,000
1,653,108,000
1,793,578,000
1,799,338,000
1,814,072,000
1,858,205,000
1,897,648,000
2,315,169,000
2,273,628,000
2,332,395,000
2,456,518,000
3,569,603,000
3,569,603,0002,456,518,0002,332,395,0002,273,628,0002,315,169,0001,897,648,0001,858,205,0001,814,072,0001,799,338,0001,793,578,0001,653,108,0001,445,561,0001,400,629,0001,335,091,0001,364,176,0001,348,446,0001,439,152,0001,470,701,0001,584,523,000913,563,000902,698,000
   > Total Current Assets 
579,061,000
657,469,000
1,050,306,000
965,984,000
977,277,000
963,640,000
988,544,000
653,154,000
781,078,000
827,190,000
913,292,000
965,958,000
897,537,000
876,665,000
845,619,000
857,159,000
867,514,000
872,588,000
923,354,000
1,049,954,000
1,194,730,000
1,194,730,0001,049,954,000923,354,000872,588,000867,514,000857,159,000845,619,000876,665,000897,537,000965,958,000913,292,000827,190,000781,078,000653,154,000988,544,000963,640,000977,277,000965,984,0001,050,306,000657,469,000579,061,000
       Cash And Cash Equivalents 
345,501,000
423,478,000
473,423,000
422,513,000
460,486,000
267,460,000
312,196,000
142,895,000
210,986,000
264,912,000
391,374,000
396,430,000
360,030,000
340,923,000
331,731,000
311,074,000
318,391,000
326,128,000
315,986,000
376,840,000
335,687,000
335,687,000376,840,000315,986,000326,128,000318,391,000311,074,000331,731,000340,923,000360,030,000396,430,000391,374,000264,912,000210,986,000142,895,000312,196,000267,460,000460,486,000422,513,000473,423,000423,478,000345,501,000
       Short-term Investments 
11,734,000
12,378,000
165,830,000
123,440,000
108,187,000
246,463,000
225,078,000
33,908,000
88,112,000
47,765,000
35,406,000
59,908,000
290,000
13,554,000
13,517,000
2,607,000
9,459,000
5,560,000
21,297,000
19,784,000
28,784,000
28,784,00019,784,00021,297,0005,560,0009,459,0002,607,00013,517,00013,554,000290,00059,908,00035,406,00047,765,00088,112,00033,908,000225,078,000246,463,000108,187,000123,440,000165,830,00012,378,00011,734,000
       Net Receivables 
150,583,000
166,983,000
299,704,000
305,988,000
305,722,000
290,546,000
291,404,000
330,315,000
336,236,000
300,121,000
332,639,000
332,923,000
358,106,000
320,803,000
327,924,000
362,741,000
370,598,000
343,178,000
382,462,000
427,965,000
534,985,000
534,985,000427,965,000382,462,000343,178,000370,598,000362,741,000327,924,000320,803,000358,106,000332,923,000332,639,000300,121,000336,236,000330,315,000291,404,000290,546,000305,722,000305,988,000299,704,000166,983,000150,583,000
       Inventory 
56,739,000
40,461,000
93,864,000
90,979,000
91,445,000
105,429,000
111,052,000
116,880,000
111,821,000
128,180,000
135,228,000
156,907,000
161,691,000
182,537,000
147,626,000
151,511,000
151,017,000
164,080,000
153,072,000
174,386,000
248,738,000
248,738,000174,386,000153,072,000164,080,000151,017,000151,511,000147,626,000182,537,000161,691,000156,907,000135,228,000128,180,000111,821,000116,880,000111,052,000105,429,00091,445,00090,979,00093,864,00040,461,00056,739,000
       Other Current Assets 
14,504,000
14,169,000
17,485,000
23,064,000
11,437,000
53,742,000
48,814,000
29,156,000
33,923,000
86,212,000
18,645,000
19,790,000
17,420,000
32,402,000
38,338,000
31,833,000
27,508,000
39,202,000
71,834,000
70,763,000
46,536,000
46,536,00070,763,00071,834,00039,202,00027,508,00031,833,00038,338,00032,402,00017,420,00019,790,00018,645,00086,212,00033,923,00029,156,00048,814,00053,742,00011,437,00023,064,00017,485,00014,169,00014,504,000
   > Long-term Assets 
323,637,000
256,094,000
534,217,000
504,717,000
461,875,000
384,806,000
375,632,000
681,937,000
619,551,000
575,929,000
694,285,000
776,421,000
901,801,000
937,407,000
1,012,586,000
1,040,489,000
1,447,655,000
1,401,040,000
1,409,041,000
1,406,564,000
2,374,873,000
2,374,873,0001,406,564,0001,409,041,0001,401,040,0001,447,655,0001,040,489,0001,012,586,000937,407,000901,801,000776,421,000694,285,000575,929,000619,551,000681,937,000375,632,000384,806,000461,875,000504,717,000534,217,000256,094,000323,637,000
       Property Plant Equipment 
174,120,000
134,675,000
206,568,000
194,556,000
179,883,000
181,447,000
184,489,000
190,160,000
199,159,000
218,479,000
191,451,000
202,869,000
200,955,000
191,115,000
181,295,000
173,483,000
268,600,000
264,623,000
269,044,000
286,459,000
293,742,000
293,742,000286,459,000269,044,000264,623,000268,600,000173,483,000181,295,000191,115,000200,955,000202,869,000191,451,000218,479,000199,159,000190,160,000184,489,000181,447,000179,883,000194,556,000206,568,000134,675,000174,120,000
       Goodwill 
0
0
0
0
29,319,000
26,377,000
22,159,000
101,255,000
94,192,000
95,978,000
116,766,000
136,337,000
150,660,000
168,521,000
212,976,000
225,864,000
278,253,000
284,011,000
303,030,000
328,411,000
418,694,000
418,694,000328,411,000303,030,000284,011,000278,253,000225,864,000212,976,000168,521,000150,660,000136,337,000116,766,00095,978,00094,192,000101,255,00022,159,00026,377,00029,319,0000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
62,608,000
105,948,000
2,428,638
130,731,000
100,003,000
104,167,000
118,479,000
0
0
0
0
0
00000118,479,000104,167,000100,003,000130,731,0002,428,638105,948,00062,608,000000000000
       Intangible Assets 
27,266,000
14,670,000
31,515,000
41,511,000
38,671,000
31,984,000
40,601,000
265,922,000
220,085,000
198,864,000
280,120,000
295,844,000
339,202,000
387,419,000
416,912,000
429,707,000
724,773,000
651,427,000
623,431,000
562,496,000
1,453,824,000
1,453,824,000562,496,000623,431,000651,427,000724,773,000429,707,000416,912,000387,419,000339,202,000295,844,000280,120,000198,864,000220,085,000265,922,00040,601,00031,984,00038,671,00041,511,00031,515,00014,670,00027,266,000
       Other Assets 
0
0
0
0
0
0
0
0
0
42,442,000
45,531,000
51,199,000
80,253,000
1,000
-1,000
92,956,000
52,875,000
54,175,000
72,330,000
84,170,000
0
084,170,00072,330,00054,175,00052,875,00092,956,000-1,0001,00080,253,00051,199,00045,531,00042,442,000000000000
> Total Liabilities 
174,843,000
170,090,000
367,182,000
371,706,000
328,289,000
318,225,000
310,243,000
313,995,000
382,506,000
383,535,000
384,632,000
475,662,000
540,129,000
542,262,000
589,916,000
639,252,000
1,026,000,000
887,514,000
872,086,000
948,564,000
1,973,615,000
1,973,615,000948,564,000872,086,000887,514,0001,026,000,000639,252,000589,916,000542,262,000540,129,000475,662,000384,632,000383,535,000382,506,000313,995,000310,243,000318,225,000328,289,000371,706,000367,182,000170,090,000174,843,000
   > Total Current Liabilities 
110,146,000
119,447,000
300,201,000
308,833,000
284,530,000
283,553,000
277,157,000
239,648,000
314,170,000
313,536,000
340,688,000
420,890,000
413,359,000
399,856,000
421,620,000
497,665,000
798,708,000
592,372,000
687,411,000
726,034,000
1,285,725,000
1,285,725,000726,034,000687,411,000592,372,000798,708,000497,665,000421,620,000399,856,000413,359,000420,890,000340,688,000313,536,000314,170,000239,648,000277,157,000283,553,000284,530,000308,833,000300,201,000119,447,000110,146,000
       Short-term Debt 
1,238,000
0
414,000
1,671,000
0
0
0
0
0
1,147,000
1,210,000
18,571
505,000
499,000
444,000
430,000
344,105,000
136,101,000
157,730,000
75,000,000
472,278,000
472,278,00075,000,000157,730,000136,101,000344,105,000430,000444,000499,000505,00018,5711,210,0001,147,000000001,671,000414,00001,238,000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
1,147,000
1,210,000
18,571
0
0
0
0
0
0
0
75,000,000
472,278,000
472,278,00075,000,000000000018,5711,210,0001,147,000000000000
       Accounts payable 
61,515,000
61,730,000
189,657,000
170,898,000
0
181,561,000
177,988,000
139,232,000
190,795,000
178,439,000
187,032,000
226,602,000
181,559,000
182,826,000
140,909,000
185,280,000
171,954,000
124,777,000
130,739,000
140,236,000
185,193,000
185,193,000140,236,000130,739,000124,777,000171,954,000185,280,000140,909,000182,826,000181,559,000226,602,000187,032,000178,439,000190,795,000139,232,000177,988,000181,561,0000170,898,000189,657,00061,730,00061,515,000
       Other Current Liabilities 
5,695,000
57,717,000
10,184,000
11,099,000
284,530,000
101,992,000
99,169,000
100,416,000
123,375,000
135,097,000
153,656,000
194,288,000
202,516,000
157,631,000
220,239,000
298,635,000
270,954,000
323,099,000
366,554,000
505,661,000
589,739,000
589,739,000505,661,000366,554,000323,099,000270,954,000298,635,000220,239,000157,631,000202,516,000194,288,000153,656,000135,097,000123,375,000100,416,00099,169,000101,992,000284,530,00011,099,00010,184,00057,717,0005,695,000
   > Long-term Liabilities 
64,697,000
50,643,000
66,981,000
62,873,000
43,759,000
34,672,000
33,086,000
74,347,000
68,336,000
70,000,000
64,000
90,000
126,770,000
142,406,000
168,296,000
141,587,000
227,292,000
295,142,000
184,675,000
222,530,000
687,890,000
687,890,000222,530,000184,675,000295,142,000227,292,000141,587,000168,296,000142,406,000126,770,00090,00064,00070,000,00068,336,00074,347,00033,086,00034,672,00043,759,00062,873,00066,981,00050,643,00064,697,000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
43,131,000
928,638
124,449,000
147,659,000
163,877,000
141,152,000
157,915,000
152,578,000
128,986,000
106,852,000
0
0106,852,000128,986,000152,578,000157,915,000141,152,000163,877,000147,659,000124,449,000928,63843,131,0000000000000
> Total Stockholder Equity
725,392,000
741,894,000
1,216,897,000
1,098,644,000
1,110,535,000
1,029,883,000
1,053,581,000
1,021,096,000
1,018,123,000
1,062,026,000
1,268,476,000
1,317,916,000
1,259,209,000
1,271,810,000
1,268,289,000
1,258,396,000
1,289,168,000
1,386,115,000
1,460,308,000
1,507,954,000
1,595,988,000
1,595,988,0001,507,954,0001,460,308,0001,386,115,0001,289,168,0001,258,396,0001,268,289,0001,271,810,0001,259,209,0001,317,916,0001,268,476,0001,062,026,0001,018,123,0001,021,096,0001,053,581,0001,029,883,0001,110,535,0001,098,644,0001,216,897,000741,894,000725,392,000
   Common Stock
99,761,000
100,491,000
102,986,000
103,001,000
103,001,000
103,000,000
103,000,000
103,000,000
103,000,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000
103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,001,000103,000,000103,000,000103,000,000103,000,000103,001,000103,001,000102,986,000100,491,00099,761,000
   Retained Earnings 
616,112,000
640,518,000
959,217,000
1,006,648,000
917,206,000
957,346,000
895,101,000
874,351,000
894,737,000
917,511,000
864,830,000
905,083,000
973,053,000
1,013,923,000
976,076,000
991,957,000
905,851,000
953,289,000
944,261,000
908,158,000
809,400,000
809,400,000908,158,000944,261,000953,289,000905,851,000991,957,000976,076,0001,013,923,000973,053,000905,083,000864,830,000917,511,000894,737,000874,351,000895,101,000957,346,000917,206,0001,006,648,000959,217,000640,518,000616,112,000
   Capital Surplus 000000000000000000000
   Treasury Stock000000000000000000000
   Other Stockholders Equity 
9,519,000
885,000
154,694,000
-11,005,000
90,328,000
-30,463,000
55,480,000
43,745,000
20,386,000
41,514,000
300,645,000
309,832,000
19,792,000
38,883,000
41,267,000
12,671,000
170,327,000
329,825,000
413,046,000
496,795,000
683,587,000
683,587,000496,795,000413,046,000329,825,000170,327,00012,671,00041,267,00038,883,00019,792,000309,832,000300,645,00041,514,00020,386,00043,745,00055,480,000-30,463,00090,328,000-11,005,000154,694,000885,0009,519,000



6.4. Balance Sheets

Currency in JPY. All numbers in thousands.




6.5. Cash Flows

Currency in JPY. All numbers in thousands.




6.6. Income Statements

Currency in JPY. All numbers in thousands.


6.7. Latest Income Statement

Income Statement (annual), 2024-03-31. Currency in JPY. All numbers in thousands.

Gross Profit (+$)
totalRevenue1,603,672,000
Cost of Revenue-292,485,000
Gross Profit1,311,187,0001,311,187,000
 
Operating Income (+$)
Gross Profit1,311,187,000
Operating Expense-1,285,669,000
Operating Income25,518,00025,518,000
 
Operating Expense (+$)
Research Development294,200,000
Selling General Administrative740,110,000
Selling And Marketing Expenses-
Operating Expense1,285,669,0001,034,310,000
 
Net Interest Income (+$)
Interest Income11,455,000
Interest Expense-12,005,000
Other Finance Cost-0
Net Interest Income-550,000
 
Pretax Income (+$)
Operating Income25,518,000
Net Interest Income-550,000
Other Non-Operating Income Expenses-
Income Before Tax (EBT)24,969,00026,067,000
EBIT - interestExpense = 24,969,000
24,969,000
29,050,000
Interest Expense12,005,000
Earnings Before Interest and Taxes (EBIT)36,974,00036,974,000
Earnings Before Interest and Taxes (EBITDA)194,814,000
 
After tax Income (+$)
Income Before Tax24,969,000
Tax Provision-7,924,000
Net Income From Continuing Ops17,045,00017,045,000
Net Income17,045,000
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses1,578,154,000
Total Other Income/Expenses Net-549,000550,000
 

Technical Analysis of Astellas
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Astellas. The general trend of Astellas is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Astellas's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Astellas Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

SupportΒ is a price level at which demand for an asset is strong enough to prevent the price from falling further.
ResistanceΒ is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Astellas Pharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 10.13 < 10.98 < 11.03.

The bearish price targets are: 9.71 > 9.4 > 9.12.

Know someone who trades $ALPMY? Share this with them.πŸ‘‡

Astellas Pharma Inc Daily Support & Resistance Chart
3rd party ad coffee SUPPORTERis ad-free.

2. Trend Indicators

2.1 Moving Averages

Shows theΒ moving averageΒ of the selected period.

  • Moving averages are laggingΒ trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Astellas Pharma Inc. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending up: The MA 20 is trending up. +1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 > MA 50: The MA 20 is higher than the MA 50. +1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Astellas Pharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows theΒ momentumΒ of theΒ selected period based on two moving averages.

  • MACD is aΒ lagging momentumΒ indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Astellas Pharma Inc. The current macd is 0.05658835.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Astellas price going down in the near term. -2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Astellas. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Astellas price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Astellas Pharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartAstellas Pharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Astellas Pharma Inc. The current adx is 10.13.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Astellas shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Astellas Pharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • ShowsΒ the current trend.
  • ShowsΒ potential entry signals.
  • ShowsΒ Β potential exit signals.
  • Can be used to placeΒ trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Astellas Pharma Inc. The current sar is 9.74564481.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Astellas Pharma Inc Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentumΒ indicator, meaning the signals are instant.
  • RangesΒ between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Astellas Pharma Inc. The current rsi is 51.13. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 3/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
Astellas Pharma Inc Daily Relative Strength Index (RSI) ChartAstellas Pharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

ComparesΒ a certain price to multiple prices ranging over time.

  • LeadingΒ momentumΒ indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • RangesΒ between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Astellas Pharma Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Astellas price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Astellas Pharma Inc Daily Stochastic Oscillator ChartAstellas Pharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero,Β the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Astellas Pharma Inc. The current cci is 4.12576469.

Astellas Pharma Inc Daily Commodity Channel Index (CCI) ChartAstellas Pharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Astellas Pharma Inc. The current cmo is -3.54565393.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Astellas Pharma Inc Daily Chande Momentum Oscillator (CMO) ChartAstellas Pharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

Β Shows the current price relative to the highest high over the last 14 days.
Β 

  • Lagging momentum indicator
  • Ranging between 0 andΒ -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Astellas Pharma Inc. The current willr is -48.38709677.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Astellas is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Astellas Pharma Inc Daily Williams %R ChartAstellas Pharma Inc Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversoldΒ 

Score

Let's take a look at the Bollinger Bands of Astellas Pharma Inc.

Astellas Pharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Astellas Pharma Inc. The current atr is 0.14037066.

Astellas Pharma Inc Daily Average True Range (ATR) ChartAstellas Pharma Inc Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Β Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Astellas Pharma Inc. The current obv is 3,768,320.

Astellas Pharma Inc Daily On-Balance Volume (OBV) ChartAstellas Pharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Astellas Pharma Inc. The current mfi is 56.44.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Astellas Pharma Inc Daily Money Flow Index (MFI) ChartAstellas Pharma Inc Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Astellas Pharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-11-01CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-04STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-05STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-11-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-08STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-11-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-15MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-18STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-11-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-11-21STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-11-26RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-11-29DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-12-03CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-12-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-12-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-12-13WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-16MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-23STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-26STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-12-27RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-12-30SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-12-31MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-15CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-16CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-24STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-01-27CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-29STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-30BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2025-01-31CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-03SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-04WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-02-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2025-02-06STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-02-10MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-12STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-13STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2025-02-18STOCH LONG EXITThe %K line crosses below the %D line.
2025-02-20STOCH SHORT EXITThe %K line crosses above the %D line.
2025-02-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-27STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-04DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2025-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-07STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-11CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-03-12STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-03-14WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2025-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-03-25STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2025-03-26MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

Astellas Pharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Astellas Pharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.126
Ma 20Greater thanMa 509.873
Ma 50Greater thanMa 1009.720
Ma 100Greater thanMa 20010.001
OpenGreater thanClose9.870
Total2/5 (40.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of Astellas with someone you think should read this too:
  • Are you bullish or bearish on Astellas? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Astellas? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Astellas Pharma Inc

I send you an email if I find something interesting about Astellas Pharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Astellas Pharma Inc.

Receive notifications about Astellas Pharma Inc in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.